Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions / Ralli, M.; Botticelli, A.; Visconti, I. C.; Angeletti, D.; Fiore, M.; Marchetti, P.; Lambiase, A.; De Vincentiis, M.; Greco, A.. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-8861. - 2020:(2020). [10.1155/2020/9235638]

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli M.
Primo
;
Botticelli A.
Secondo
;
Visconti I. C.;Angeletti D.;Marchetti P.;Lambiase A.;De Vincentiis M.
Penultimo
;
Greco A.
Ultimo
2020

Abstract

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.
2020
melanoma
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions / Ralli, M.; Botticelli, A.; Visconti, I. C.; Angeletti, D.; Fiore, M.; Marchetti, P.; Lambiase, A.; De Vincentiis, M.; Greco, A.. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-8861. - 2020:(2020). [10.1155/2020/9235638]
File allegati a questo prodotto
File Dimensione Formato  
Ralli_Immunotherapy_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1524920
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 101
  • ???jsp.display-item.citation.isi??? 97
social impact